Antipruritic therapy issues on background of skin xerosis

The relationship of xerosis with various skin diseases is very multifaceted, at the same time, xerosis can be the cause of the onset or aggravation of itching. Modern recommendations for the external treatment of chronic dermatoses, accompanied by xerosis and itching, imply two directions: direct therapeutic measures during an exacerbation and the use of dermatocosmetics adapted to certain symptoms.Material and methods. We observed 26 patients (mean age 38.7 ± 1.9 years with atopic dermatitis, eczema, psoriasis or pruritus, where xerosis was present in the clinical picture and pruritus was noted. All patients used topical drugs in accordance with the nosology, in as an adjuvant therapy – Neotanin Comfort Plus cream.Research results. In atopic dermatitis, the corneometry index increased by an average of 21%, with eczema – by 20%, with psoriasis – by 22%, with skin itching – by 12%. Transepidermal water loss decreased in atopic dermatitis by 19.8%, with eczema – by 22.8%, with psoriasis – by 21.8%, with pruritus – by 18.4% The value of the total BRS index decreased by more than two times.Conclusion. The use of Neotanin Comfort Plus cream in combination with topical drug therapy (GCS, multicomponent drugs) is highly effective and safe in patients with atopic dermatitis, eczema, psoriasis or pruritus, which makes it possible to recommend it for use in wide clinical practice.

Antipruritic therapy as main component of improving quality of life of patients with dermatoses

Itchy skin, a symptom of various diseases, present in 54.4 % of patients with skin pathologies, is a rather difficult task when choosing a therapy.Material and methods. Under observation were 45 patients (27 women and 18 men) with various dermatoses, accompanied by itching. All patients received Neotanin therapy (cream and spray) with standard topical therapy. Efficiency assessment was carried out taking into account the indices Prurindex, BRS, dermatological status indices for each nosology (SCORAD, EASI, PASI), and DIC.Results. In patients with idiopathic skin itching, Prurindex decreased by 100 % by the end of 3rd weeks, BRS – by 96.8 %. In atopic dermatitis, the SCORAD index decreased by 78.3 %, BRS index reduced by 91.9 %, Prurindex index decreased by 95.4 %. With eczema, the EASI index decreased by 96.1 %, the BRS and Prurindex index were reduced by 100 %. In psoriasis, the PASI index decreased by 86.5 %, BRS index – by 90.8 %, Prurindex index – by 94.2 %.Conclusions. The use of the topical Neotanin as monotherapy for idiopathic pruritus, as a part of comprehensive treatment for atopic dermatitis, eczema, psoriasis, significantly improves the quality of life of patients.